Caffeine as symptomatic treatment for Parkinson disease (Cafe-PD): A randomized trial.

ABSTRACT:

Objective

To assess effects of caffeine on Parkinson disease (PD).

Methods

In this multicenter parallel-group controlled trial, patients with PD with 1-8 years disease duration, Hoehn & Yahr stages I-III, on stable symptomatic therapy were randomized to caffeine 200 mg BID vs matching placebo capsules for 6-18 months. The primary research question was whether objective motor scores would differ at 6 months (Movement Disorder Society-sponsored Unified Parkinson's Disease Rating Scale [MDS-UPDRS]-III, Class I evidence). Secondary outcomes included safety and tolerability, motor symptoms (MDS-UPDRS-II), motor fluctuations, sleep, nonmotor symptoms (MDS-UPDRS-I), cognition (Montreal Cognitive Assessment), and quality of life.

Results

Sixty patients received caffeine and 6

SUBMITTER: Postuma RB 

PROVIDER: S-EPMC5664303 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature